BIO COMPOSANTS MEDICAUX : revenue, balance sheet and financial ratios

BIO COMPOSANTS MEDICAUX is a French company founded 32 years ago, specialized in the sector Fabrication de matériel médico-chirurgical et dentaire. Based in SAINT-BLAISE-DU-BUIS (38140), this company of category PME shows in 2017 a revenue of 1.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - BIO COMPOSANTS MEDICAUX (SIREN 394152383)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C N/C N/C 1 445 441 € 1 144 638 €
Net income 61 093 € 45 583 € -111 848 € -451 397 € -127 197 € -104 352 € 174 170 € 217 140 € 124 339 €
EBITDA N/C N/C N/C N/C N/C N/C N/C 409 863 € 241 281 €
Net margin N/C N/C N/C N/C N/C N/C N/C 15.0% 10.9%

Revenue and income statement

In 2024, BIO COMPOSANTS MEDICAUX generates positive net income of 61 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 124 k€ -> 61 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

61 093 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 173%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 26%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

173.382%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

25.882%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

16.9%

Solvency indicators evolution
BIO COMPOSANTS MEDICAUX

Sector positioning

Debt ratio
173.38 2024
2022
2023
2024
Q1: 1.92
Med: 18.86
Q3: 55.42
Average

In 2024, the debt ratio of BIO COMPOSANTS MEDICAUX (173.38) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
25.88% 2024
2022
2023
2024
Q1: 24.8%
Med: 50.27%
Q3: 69.09%
Average

In 2024, the financial autonomy of BIO COMPOSANTS MEDICAUX (25.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 293.82. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

293.823

Liquidity indicators evolution
BIO COMPOSANTS MEDICAUX

Sector positioning

Liquidity ratio
293.82 2024
2022
2023
2024
Q1: 159.64
Med: 253.69
Q3: 429.69
Good +31 pts over 3 years

In 2024, the liquidity ratio of BIO COMPOSANTS MEDICAUX (293.82) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
BIO COMPOSANTS MEDICAUX

Positioning of BIO COMPOSANTS MEDICAUX in its sector

Comparison with sector Fabrication de matériel médico-chirurgical et dentaire

Valuation estimate

Based on 57 transactions of similar company sales (all years), the value of BIO COMPOSANTS MEDICAUX is estimated at 186 069 € (range 43 240€ - 366 921€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
57 tx
43k€ 186k€ 366k€
186 069 € Range: 43 240€ - 366 921€
NAF 5 all-time

Valuation method used

Net Income Multiple
61 093 € × 3.0x = 186 070 €
Range: 43 240€ - 366 921€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 57 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication de matériel médico-chirurgical et dentaire)

Compare BIO COMPOSANTS MEDICAUX with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de matériel médico-chirurgical et dentaire

Frequently asked questions about BIO COMPOSANTS MEDICAUX

What is the revenue of BIO COMPOSANTS MEDICAUX ?

The revenue of BIO COMPOSANTS MEDICAUX in 2017 is 1.4 M€.

Is BIO COMPOSANTS MEDICAUX profitable?

Yes, BIO COMPOSANTS MEDICAUX generated a net profit of 61 k€ in 2024.

Where is the headquarters of BIO COMPOSANTS MEDICAUX ?

The headquarters of BIO COMPOSANTS MEDICAUX is located in SAINT-BLAISE-DU-BUIS (38140), in the department Isere.

Where to find the tax return of BIO COMPOSANTS MEDICAUX ?

The tax return of BIO COMPOSANTS MEDICAUX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does BIO COMPOSANTS MEDICAUX operate?

BIO COMPOSANTS MEDICAUX operates in the sector Fabrication de matériel médico-chirurgical et dentaire (NAF code 32.50A). See the 'Sector positioning' section above to compare the company with its competitors.